
NYSEHealthcareDrug Manufacturers - Specialty & Generic
Latest quote
$14.50
−$0.05 · -0.34%
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Previous close
$14.50
−$0.05 · -0.34%
After-hours
$14.50
$0.00 · 0.00%
Oct 8, 4:00 PM ET
Regular session · ET · Market data may be delayed.
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Day range
Current $14.50
52-week range
Current $14.50
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
65
Undervalued
Sentiment
56
Mixed
Risk
58
Elevated Risk
Momentum
26
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Day range
Current $14.50
52-week range
Current $14.50
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.25B USD | 4.37B USD | 4.66B USD | 4.45B USD | 4.14B USD |
| Cost of goods sold | 2.76B USD | 2.83B USD | 2.98B USD | 3B USD | 2.72B USD |
| Gross profit | 1.49B USD | 1.54B USD | 1.68B USD | 1.46B USD | 1.42B USD |
| Research and development | 95.4M USD | 112.2M USD | 122.5M USD | 123.1M USD | 122M USD |
| Selling, general, and administrative | 526.5M USD | 1.11B USD | 1.27B USD | 1.21B USD | 1.11B USD |
| Operating expenses | 1.15B USD | 1.43B USD | 1.53B USD | 1.38B USD | 1.01B USD |
| Interest expense | 162.5M USD | 187.8M USD | 173.8M USD | 156M USD | 125M USD |
| Depreciation and amortization | 337.5M USD | 325.9M USD | 359.5M USD | 338.6M USD | 312.2M USD |
| Operating income | 343.3M USD | 112.9M USD | 151.9M USD | 78.9M USD | 410.4M USD |
| Net income | −1.43B USD | −171.8M USD | −12.7M USD | −140.6M USD | −68.9M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$36.20
149.66% upsideCash distributions grouped by calendar year; partial years are marked.
$1.16
2025 complete year+20.8% since 2021
2026 partial: $0.87
$0.96
2,021
$1.04
2,022
$1.092
2,023
$1.104
2,024
$1.16
2,025
$0.87
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Aug 28, 2026 | $0.29Quarterly | Aug 28, 2026 | Sep 15, 2026 |
Dividend | May 29, 2026 | $0.29Quarterly | May 29, 2026 | Jun 16, 2026 |
Dividend | Mar 2, 2026 | $0.29Quarterly | Mar 2, 2026 | Mar 24, 2026 |
Dividend | Nov 28, 2025 | $0.29Quarterly | Nov 28, 2025 | Dec 16, 2025 |
Dividend | Aug 29, 2025 | $0.29Quarterly | Aug 29, 2025 | Sep 16, 2025 |
Dividend | May 30, 2025 | $0.29Quarterly | May 30, 2025 | Jun 17, 2025 |
Ex-dividend Aug 28, 2026
$0.29
Quarterly
Record Aug 28, 2026 · Payment Sep 15, 2026
Ex-dividend May 29, 2026
$0.29
Quarterly
Record May 29, 2026 · Payment Jun 16, 2026
Ex-dividend Mar 2, 2026
$0.29
Quarterly
Record Mar 2, 2026 · Payment Mar 24, 2026
Ex-dividend Nov 28, 2025
$0.29
Quarterly
Record Nov 28, 2025 · Payment Dec 16, 2025
Ex-dividend Aug 29, 2025
$0.29
Quarterly
Record Aug 29, 2025 · Payment Sep 16, 2025
Ex-dividend May 30, 2025
$0.29
Quarterly
Record May 30, 2025 · Payment Jun 17, 2025
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR120.69M0.12%102.88B USD0.06%$137.31+0.17%
Vanguard Morningstar Total Stock Market ETFVTI64.7M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM53.79M0.07%77.7B USD0.19%$277.57-0.05%
Vanguard Morningstar Small-Cap ETFVB46.54M0.02%185.3B USD0.03%$287.63+0.23%
Invesco High Yield Equity Dividend Achievers ETFPEY40.24M3.77%1.07B USD0.68%$23.09+1.12%
Vanguard Morningstar Small-Cap Value ETFVBR29.6M0.04%68.2B USD0.05%$233.91+0.75%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV26.73M0.10%26.69B USD0.33%$38.10+0.82%
Vanguard Extended Market ETFVXF23.55M0.02%95.4B USD0.05%$233.13-0.15%
iShares Core S&P Small-Cap ETFIJR
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Small-Cap ETFVB
Invesco High Yield Equity Dividend Achievers ETFPEY
Vanguard Morningstar Small-Cap Value ETFVBR
U.S. Small Cap Value Portfolio ETF Class SharesDFSV
Vanguard Extended Market ETFVXFAI-generated and delayed market data for informational and educational purposes only. Not investment advice.